Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis

Trial Profile

CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms CANDLE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 Apr 2017 Last checked against ClinicalTrials.gov record.
    • 01 May 2010 MRI results published in the Journal of Rheumatology.
    • 15 Mar 2010 Results published in the Journal of Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top